BioAdaptives Statistics
Total Valuation
BioAdaptives has a market cap or net worth of 30,759. The enterprise value is 524,399.
| Market Cap | 30,759 |
| Enterprise Value | 524,399 |
Important Dates
The next estimated earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAdaptives has 15.94 million shares outstanding. The number of shares has increased by 26.42% in one year.
| Current Share Class | 15.94M |
| Shares Outstanding | 15.94M |
| Shares Change (YoY) | +26.42% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | n/a |
| Float | 15.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.20 |
| PB Ratio | -0.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04
| Current Ratio | 0.04 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.20 |
| Interest Coverage | -3.57 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -323.53% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 51.48% |
| Weighted Average Cost of Capital (WACC) | 36.94% |
| Revenue Per Employee | 25,561 |
| Profits Per Employee | -1.16M |
| Employee Count | 1 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.15 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.64% in the last 52 weeks. The beta is 1.29, so BioAdaptives's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -90.64% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 45.76 |
| Average Volume (20 Days) | 37,519,957 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioAdaptives had revenue of 25,561 and -1.16 million in losses. Loss per share was -0.10.
| Revenue | 25,561 |
| Gross Profit | 19,787 |
| Operating Income | -909,200 |
| Pretax Income | -1.16M |
| Net Income | -1.16M |
| EBITDA | -903,200 |
| EBIT | -909,200 |
| Loss Per Share | -0.10 |
Balance Sheet
The company has 29,221 in cash and 522,725 in debt, with a net cash position of -493,504 or -0.03 per share.
| Cash & Cash Equivalents | 29,221 |
| Total Debt | 522,725 |
| Net Cash | -493,504 |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -1.77M |
| Book Value Per Share | -0.05 |
| Working Capital | -1.78M |
Cash Flow
| Operating Cash Flow | -436,361 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5,015 |
| Net Borrowing | 255,000 |
| Free Cash Flow | -436,361 |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 77.41% |
| Operating Margin | -3,556.98% |
| Pretax Margin | -4,553.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAdaptives does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.42% |
| Shareholder Yield | -26.42% |
| Earnings Yield | -3,783.75% |
| FCF Yield | -1,418.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 23, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Jan 23, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |